BioSante Pharmaceuticals Inc. said it will raise $25.1 million in a registered direct offering to support several ongoing clinical trials of its testosterone gel product, Libigel. Pursuant to a prior shelf registration, the Lincolnshire, Ill.-based company will sell 12.2 million shares of common stock and warrants to several institutional investors, with total net proceeds estimated at $23.8 million.